|
1
|
Cersosimo F, Lonardi S, Bernardini G,
Telfer B, Mandelli GE, Santucci A, Vermi W and Giurisato E:
Tumor-associated macrophages in osteosarcoma: From mechanisms to
therapy. Int J Mol Sci. 21:52072020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shoaib Z, Fan TM and Irudayaraj JMK:
Osteosarcoma mechanobiology and therapeutic targets. Br J
Pharmacol. 179:201–217. 2022. View Article : Google Scholar :
|
|
3
|
Chen C, Xie L, Ren T, Huang Y, Xu J and
Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism,
rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021.
View Article : Google Scholar
|
|
4
|
Jafari F, Javdansirat S, Sanaie S, Naseri
A, Shamekh A, Rostamzadeh D and Dolati S: Osteosarcoma: A
comprehensive review of management and treatment strategies. Ann
Diagn Pathol. 49:1516542020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li S, Zhang H, Liu J and Shang G: Targeted
therapy for osteosarcoma: A review. J Cancer Res Clin Oncol.
149:6785–6797. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang J, Guo J and Jia R:
N6-methyladenosine methyltransferase component KIAA1429 is a
potential target of cancer therapy. Biomolecules. 14:13192024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Li MJ, Xia L and Zhang H: The
biological function of m6A methyltransferase KIAA1429 and its role
in human disease. PeerJ. 10:e143342022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ren M, Pan H, Zhou X, Yu M and Ji F:
KIAA1429 promotes gastric cancer progression by destabilizing RASD1
mRNA in an m6A-YTHDF2-dependent manner. J Transl Med.
22:5842024. View Article : Google Scholar
|
|
9
|
Li N, Zhu Z, Deng Y, Tang R, Hui H, Kang Y
and Rana TM: KIAA1429/VIRMA promotes breast cancer progression by
m6 A-dependent cytosolic HAS2 stabilization. EMBO Rep.
24:e555062023.
|
|
10
|
Li J, Rao B, Yang J, Liu L, Huang M, Liu
X, Cui G, Li C, Han Q, Yang H, et al: Dysregulated m6A-related
regulators are associated with tumor metastasis and poor prognosis
in osteosarcoma. Front Oncol. 10:7692020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y,
Sun Y, Zeng F, Chen X and Deng G: Ferroptosis in cancer: From
molecular mechanisms to therapeutic strategies. Signal Transduct
Target Ther. 9:552024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Kang R and Tang D: Signaling
pathways and defense mechanisms of ferroptosis. FEBS J.
289:7038–7050. 2022. View Article : Google Scholar
|
|
13
|
Zhao J, Zhao Y, Ma X, Zhang B and Feng H:
Targeting ferroptosis in osteosarcoma. J Bone Oncol. 30:1003802021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q
and Jin H: SLC7A11/xCT in cancer: Biological functions and
therapeutic implications. Am J Cancer Res. 10:3106–3126.
2020.PubMed/NCBI
|
|
15
|
Rochette L, Dogon G, Rigal E, Zeller M,
Cottin Y and Vergely C: Lipid peroxidation and iron metabolism: Two
corner stones in the homeostasis control of ferroptosis. Int J Mol
Sci. 24:4492022. View Article : Google Scholar
|
|
16
|
Zhang L, Luo D, Ren H, Fan W, Yu Z, Wang
S, Wu X, Xu Y and Li S: Brusatol induced ferroptosis in
osteosarcoma cells by modulating the Keap1/Nrf2/SLC7A11 signaling
pathway. Phytomedicine. 144:1569122025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie C, Xiao Y, Yang L and Luo J: KIAA1429
silencing ameliorates osteosarcoma progression through promoting
ferroptosis via Nrf2/NQO1 axis. Inflamm Res. 74:1112025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Wang X, Chen Q, Bing Z, Zhou S, Xu Z, Hou
Y, Zhao Y, Zhao S and Wang T: Low expression of m6A reader YTHDC1
promotes progression of ovarian cancer via PIK3R1/STAT3/GANAB axis.
Int J Biol Sci. 19:4672–4688. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji FH, Fu XH, Li GQ, He Q and Qiu XG: FTO
prevents thyroid cancer progression by SLC7A11 m6A methylation in a
ferroptosis-dependent manner. Front Endocrinol (Lausanne).
13:8577652022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, Chen W, Cui Y, Gong H and Li H:
KIAA1429 protects hepatocellular carcinoma cells from ferroptotic
cell death with a m6 A-dependent posttranscriptional
modification of SLC7A11. J Cell Mol Med. 27:4118–4132. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haynes L, Kaste SC, Ness KK, Wu J,
Ortega-Laureano L, Bishop M, Neel M, Rao B and Fernandez-Pineda I:
Pathologic fracture in childhood and adolescent osteosarcoma: A
single-institution experience. Pediatr Blood Cancer. 64: View Article : Google Scholar : 2017.
|
|
23
|
Liu H, Tian L, Mu J, He X, Zhuangzhuang L,
Gong T, Wang J, Min L, Lu M and Tu C: The resection of extraosseous
osteosarcoma was accompanied by the occurrence of pulmonary
metastasis and distal metastasis at the primary site: A case
report. Front Oncol. 15:15497222025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uddin MB, Wang Z and Yang C: The
m6A RNA methylation regulates oncogenic signaling
pathways driving cell malignant transformation and carcinogenesis.
Mol Cancer. 20:612021. View Article : Google Scholar
|
|
25
|
An Y and Duan H: The role of m6A RNA
methylation in cancer metabolism. Mol Cancer. 21:142022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu T, Wang G, Wang D, Deng Y and Wang W:
m6A methylation modification: Potential pathways to suppress
osteosarcoma metastasis. Int Immunopharmacol. 145:1137592025.
View Article : Google Scholar
|
|
27
|
Miao W, Chen J, Jia L, Ma J and Song D:
The m6A methyltransferase METTL3 promotes osteosarcoma progression
by regulating the m6A level of LEF1. Biochem Biophys Res Commun.
516:719–725. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yadav P, Subbarayalu P, Medina D, Nirzhor
S, Timilsina S, Rajamanickam S, Eedunuri VK, Gupta Y, Zheng S,
Abdelfattah N, et al: M6A RNA methylation regulates histone
ubiquitination to support cancer growth and progression. Cancer
Res. 82:1872–1889. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quan H, Zhou H, Chen F, Chen J, He Y, Xiao
H, Liu J, Shi L, Xie W, Chen P and Luo J: Acetylated KIAA1429 by
TIP60 facilitates metastasis and immune evasion of hepatocellular
carcinoma via N6-methyladenosine-KDM5B-mediated regulation of
FoxO1. Cell Death Discov. 11:2102025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li P, Lu Y, Zheng Z, Lv J and Hu J: The
role and mechanism of KIAA1429-mediated m6A modification in
pancreatic adenocarcinoma. Mol Carcinog. 64:1667–1682. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen X, Lu T, Cai Y, Han Y, Ding M, Chu Y,
Zhou X and Wang X: KIAA1429-mediated m6A modification of CHST11
promotes progression of diffuse large B-cell lymphoma by regulating
Hippo-YAP pathway. Cell Mol Biol Lett. 28:322023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma L, Lin Y, Sun SW, Xu J, Yu T, Chen WL,
Zhang LH, Guo YC, Wang YW, Chen T, et al: KIAA1429 is a potential
prognostic marker in colorectal cancer by promoting the
proliferation via downregulating WEE1 expression in an
m6A-independent manner. Oncogene. 41:692–703. 2022. View Article : Google Scholar
|
|
33
|
Zhang Y, Bao Y, Zhai H, Li C, Shi H, Gong
K and Bao X: KIAA1429-mediated ZFPM2-AS1 m6A
modification promotes the proliferation, migration and invasion of
osteosarcoma cells. Oncol Lett. 30:4532025.
|
|
34
|
Luo J, Wang X, Chen Z, Zhou H and Xiao Y:
The role and mechanism of JAK2/STAT3 signaling pathway regulated by
m6A methyltransferase KIAA1429 in osteosarcoma. J Bone Oncol.
39:1004712023. View Article : Google Scholar :
|
|
35
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar :
|
|
36
|
Guo W, Wang X, Lu B, Yu J, Xu M, Huang R,
Cheng M, Yang M, Zhao W and Zou C: Super-enhancer-driven MLX
mediates redox balance maintenance via SLC7A11 in osteosarcoma.
Cell Death Dis. 14:4392023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen L, Zhang J, Zheng Z, Yang F, Liu S,
Wu Y, Chen Y, Xu T, Mao S, Yan Y, et al: PHGDH inhibits ferroptosis
and promotes malignant progression by upregulating SLC7A11 in
bladder cancer. Int J Biol Sci. 18:5459–5474. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fantone S, Piani F, Olivieri F, Rippo MR,
Sirico A, Di Simone N, Marzioni D and Tossetta G: Role of
SLC7A11/xCT in ovarian cancer. Int J Mol Sci. 25:5872024.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Shen N, Wang Z, Yu L, Yang S, Wang
Y, Liu Y, Han G and Zhang Q: TRIM3 facilitates ferroptosis in
non-small cell lung cancer through promoting SLC7A11/xCT K11-linked
ubiquitination and degradation. Cell Death Differ. 31:53–64. 2024.
View Article : Google Scholar
|
|
40
|
Zhang X, Zheng X, Ying X, Xie W, Yin Y and
Wang X: CEBPG suppresses ferroptosis through transcriptional
control of SLC7A11 in ovarian cancer. J Transl Med. 21:3342023.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zou Q, Zhou X, Lai J, Zhou H, Su J, Zhang
Z, Zhuang X, Liu L, Yuan R, Li S, et al: Targeting p62 by
sulforaphane promotes autolysosomal degradation of SLC7A11,
inducing ferroptosis for osteosarcoma treatment. Redox Biol.
79:1034602025. View Article : Google Scholar
|
|
42
|
Chen M, Jiang Y and Sun Y: KDM4A-mediated
histone demethylation of SLC7A11 inhibits cell ferroptosis in
osteosarcoma. Biochem Biophys Res Commun. 550:77–83. 2021.
View Article : Google Scholar : PubMed/NCBI
|
